Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million, days after the drugmaker won U.S. approval for its peanut allergy therapy, touted as a potential blockbuster.
The funding brings Nestle’s total investment to $473 million, increasing the Swiss company’s stake to 19.9% of Aimmune’s outstanding stock and voting power.
Aimmune shares rose 5.7% in early morning trading, after falling 11% on Tuesday. Its therapy, Palforzia, was approved on Friday after markets close.
Nestle’s investment is an incremental positive for Aimmune’s shares, which have seen some weakness due to investor worries over financing, Piper Sandler analyst Christopher Raymond wrote in a note.
“With this additional investment, we think the prospect of an outright take out by Nestle (or anyone else for that matter) has to be factored in more than before,” Raymond said.
Nestle has been trying to become a “nutrition, health and wellness” company, with its Nestle Health Science unit playing a pivotal role, as packaged food sales slow amid changing tastes.
The unit invested $145 million in Aimmune in 2016, followed by $30 million as part of the drugmaker’s public offering in February 2018, and another $98 million in November 2018.
Did You See This CB Softwares?
37 SOFTWARE TOOLS... FOR $27!?Join Affiliate Bots Right Away
Aimmune would use the latest Nestle investment to fund the launch of Palforzia, which is the first approved therapy for reducing and potentially eliminating allergic reactions to peanuts in children.
Baird analyst Brian Skorney suspects a potential for short squeeze as some decide to cover rather than wait for the performance of Palforzia in the first couple of quarters against modest expectations.
Short interest, a measure of how much money is betting on the stock to go lower, in Aimmune stood at nearly 25% of the float, as of Jan. 15, according to Refinitiv data.
Shares of heavily shorted companies can get pushed higher as traders rush to buy stock to cover their short bets, triggering what is known as a “short squeeze.”
Separately, California-based Aimmune said it had obtained a worldwide license to an experimental therapy for allergic asthma from Xencor Inc for an upfront payment of $5 million in cash and $5 million in equity. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur, Maju Samuel and Shinjini Ganguli)